数据中心
龙虎榜
大单追踪
资金流向
业绩预告
新股申购
行情中心
沪深市场
香港市场
美国市场
全球市场
行业风云
全球市场
向上 向下

董事介绍

注:董事持股数取自最新公司公告

姓名 性别 职位 年龄 薪酬 持股数(万股) 截止日期
Hung Wen Chen 男 Chairman of the Board and Chief Executive Officer and Director 64 未披露 未持股 2026-07-20
Chen, Hong Jung 男 Independent Director 66 未披露 0.82 2026-07-20
Yi Kuei Chen 男 Chief Operating Officer and Director 56 未披露 12.02 2026-07-20
Ya Chi Huang 女 Independent Director 47 未披露 0.10 2026-07-20
Hsien Shu Tsai 男 Independent Director 57 未披露 未持股 2026-07-20
Hung Hsien Yen 男 Independent Director -- 未披露 未持股 2026-07-20

高管介绍

注:高管持股数取自最新公司公告

姓名 性别 职位 年龄 薪酬 持股数(万股) 截止日期
Hung Wen Chen 男 Chairman of the Board and Chief Executive Officer and Director 64 未披露 未持股 2026-07-20
Peter Lin 男 Chief Financial Officer 57 未披露 2.23 2026-07-20
Yi Kuei Chen 男 Chief Operating Officer and Director 56 未披露 12.02 2026-07-20

董事简历

中英对照 |  中文 |  英文
Hung Wen Chen

Hung Wen Chen是中国公民台湾居民。


Hung Wen Chen has served as Chairman and Chief Executive Officer since September 2025. Mr. Chen is the Founder and Chairman of Gemtek Technology Co., Ltd. and the former Chairman and CEO of Polaris Pharmaceuticals, Inc., currently serving as an Executive Director of Polaris. In 2019, under his leadership, Polaris underwent a comprehensive strategic reorganization, achieving a remarkable turnaround that culminated in a successful IPO in Taiwan in June 2022. He began his career at Taiwan Semiconductor Manufacturing Company (TSMC), where he was engaged in research and development of semiconductor processes and integrated circuits. Mr. Chen holds a Bachelor of Physics and a Master of Electronics Engineering from National Tsing Hua University, Taiwan.
Hung Wen Chen是中国公民台湾居民。
Hung Wen Chen has served as Chairman and Chief Executive Officer since September 2025. Mr. Chen is the Founder and Chairman of Gemtek Technology Co., Ltd. and the former Chairman and CEO of Polaris Pharmaceuticals, Inc., currently serving as an Executive Director of Polaris. In 2019, under his leadership, Polaris underwent a comprehensive strategic reorganization, achieving a remarkable turnaround that culminated in a successful IPO in Taiwan in June 2022. He began his career at Taiwan Semiconductor Manufacturing Company (TSMC), where he was engaged in research and development of semiconductor processes and integrated circuits. Mr. Chen holds a Bachelor of Physics and a Master of Electronics Engineering from National Tsing Hua University, Taiwan.
Chen, Hong Jung

Chen, Hong Jung担任Apollomics Inc.董事会成员。陈博士自2018年5月起担任Maxpro Ventures LTD的董事总经理,Maxpro Ventures LTD是一家专注于突破性生物医学技术公司的投资公司,曾担任Maxpro的董事会主席和首席执行官。此前,2014年10月至2017年1月,陈博士在台湾SyneuRX International Corp.担任副总裁兼代理首席运营官,负责监督公司的日常运营,并亲自与VC代表和私人投资者互动。陈博士在制定和实施小分子、生物制剂和细胞治疗的基础研究和临床前开发战略方面拥有20多年的经验,在推进候选药物从发现到提名IND和开发方面也很有经验。陈博士在罗格斯大学、新泽西州立大学和新泽西医学与牙科大学获得微生物学和分子遗传学博士学位。他在加州理工学院完成了神经科学的博士后培训。


Chen, Hong Jung,serves as a member of board of directors. Dr. Chen was Managing Director of Maxpro Ventures LTD from May 2018 to February 2024, which is an investment firm focused on breakthrough biomedical technology companies, and served as Chairman of the Board of Directors and Chief Executive Officer of Maxpro Capital Acquisition Corp. from June 2021 to March 2023. Dr. Chen is also an ad hoc reviewer of Stem Cells Translational Medicine, and has served as director of Uneuron Biomedical Co. Ltd. since March 2023, and has been a supervisor of ReVasgen Inc. since October 2014. Previously, from October 2014 to January 2017, Dr. Chen worked as Vice President and Acting Chief Operating Officer for SyneuRx International Corp. in Taiwan, where he was responsible for supervising the company's daily operation and personally interacting with VC representatives and private investors. Dr. Chen has more than 20 years of experience in formulating and implementing basic research and preclinical development strategies for small molecules, biologics and cell therapy and is also experienced in advancing drug candidates from discovery to nomination for IND and development. Dr. Chen received his Ph.D. in Microbiology and Molecular Genetics from Rutgers, The State University of New Jersey and The University of Medicine and Dentistry of New Jersey. He completed his postdoctoral training in neuroscience at California Institute of Technology.
Chen, Hong Jung担任Apollomics Inc.董事会成员。陈博士自2018年5月起担任Maxpro Ventures LTD的董事总经理,Maxpro Ventures LTD是一家专注于突破性生物医学技术公司的投资公司,曾担任Maxpro的董事会主席和首席执行官。此前,2014年10月至2017年1月,陈博士在台湾SyneuRX International Corp.担任副总裁兼代理首席运营官,负责监督公司的日常运营,并亲自与VC代表和私人投资者互动。陈博士在制定和实施小分子、生物制剂和细胞治疗的基础研究和临床前开发战略方面拥有20多年的经验,在推进候选药物从发现到提名IND和开发方面也很有经验。陈博士在罗格斯大学、新泽西州立大学和新泽西医学与牙科大学获得微生物学和分子遗传学博士学位。他在加州理工学院完成了神经科学的博士后培训。
Chen, Hong Jung,serves as a member of board of directors. Dr. Chen was Managing Director of Maxpro Ventures LTD from May 2018 to February 2024, which is an investment firm focused on breakthrough biomedical technology companies, and served as Chairman of the Board of Directors and Chief Executive Officer of Maxpro Capital Acquisition Corp. from June 2021 to March 2023. Dr. Chen is also an ad hoc reviewer of Stem Cells Translational Medicine, and has served as director of Uneuron Biomedical Co. Ltd. since March 2023, and has been a supervisor of ReVasgen Inc. since October 2014. Previously, from October 2014 to January 2017, Dr. Chen worked as Vice President and Acting Chief Operating Officer for SyneuRx International Corp. in Taiwan, where he was responsible for supervising the company's daily operation and personally interacting with VC representatives and private investors. Dr. Chen has more than 20 years of experience in formulating and implementing basic research and preclinical development strategies for small molecules, biologics and cell therapy and is also experienced in advancing drug candidates from discovery to nomination for IND and development. Dr. Chen received his Ph.D. in Microbiology and Molecular Genetics from Rutgers, The State University of New Jersey and The University of Medicine and Dentistry of New Jersey. He completed his postdoctoral training in neuroscience at California Institute of Technology.
Yi Kuei Chen

Yi Kuei,独立董事,具有生物技术和风险投资背景,自2013年以来是Maxpro Ventures Ltd.的联合创始人兼董事总经理。陈先生在资产管理方面的专业知识使他成功地在美国和亚太地区执行了60多个私募股权投资交易。在联合创立Maxpro Ventures Ltd.之前,他从2012年7月到2013年9月担任Integral Group的高级董事,在那里他共同负责Integral’;的亚洲交易流程,管理其上海品牌,并担任多个投资组合公司的董事会成员,如Generon Corporation,FusionVax,Inc.和BioLite Inc.。从1999年4月到2012年6月,Chen先生在Central Investment Holdings的投资部门担任多个高级管理职位。在此期间,他的成功投资包括Tanox和Biopure等。此外,陈先生自2015年5月起担任风险投资基金Maxpro Investment Co.,Ltd.的董事,Maxpro Capital Management Ltd.自2015年5月起担任管理公司Vertex Ventures Ltd.的董事,Vertex Ventures Ltd.是一家管理公司,自2017年10月起担任Crystal Capital Management Ltd.的董事,自2018年10月以来。陈先生获得了锡拉丘兹大学的工商管理硕士学位和明尼苏达大学的硕士学位。


Yi Kuei Chen has served as Apollomics Inc.'s Chief Operating Officer and Director since September 2025. With backgrounds in biotechnology and venture capital, he is a co founder of Maxpro Ventures, where he successfully executed more than 60 private equity investment transactions. Mr. Chen also serves as a member of the Board of Directors of Maxpro Investment Co., Ltd., which is a major shareholder of the Company (see Item 7.A. "Major Shareholders and Related Party Transactions—Major Shareholders."). Before co founding Maxpro, Mr. Chen was the Senior Director of Integral Group, managed its Shanghai branch, and served as a board member of multiple portfolio companies such as Generon Corporation, FusionVax, Inc., BioLite, Inc., and Flora International Group Co., Ltd. From 1999 to 2012, Mr. Chen held various senior management positions in the investment division at Central Investment Holdings. He also served on several corporate boards, such as Concord Fund Company, Singfor Life Insurance Company, and CTCI Corporation.
Yi Kuei,独立董事,具有生物技术和风险投资背景,自2013年以来是Maxpro Ventures Ltd.的联合创始人兼董事总经理。陈先生在资产管理方面的专业知识使他成功地在美国和亚太地区执行了60多个私募股权投资交易。在联合创立Maxpro Ventures Ltd.之前,他从2012年7月到2013年9月担任Integral Group的高级董事,在那里他共同负责Integral’;的亚洲交易流程,管理其上海品牌,并担任多个投资组合公司的董事会成员,如Generon Corporation,FusionVax,Inc.和BioLite Inc.。从1999年4月到2012年6月,Chen先生在Central Investment Holdings的投资部门担任多个高级管理职位。在此期间,他的成功投资包括Tanox和Biopure等。此外,陈先生自2015年5月起担任风险投资基金Maxpro Investment Co.,Ltd.的董事,Maxpro Capital Management Ltd.自2015年5月起担任管理公司Vertex Ventures Ltd.的董事,Vertex Ventures Ltd.是一家管理公司,自2017年10月起担任Crystal Capital Management Ltd.的董事,自2018年10月以来。陈先生获得了锡拉丘兹大学的工商管理硕士学位和明尼苏达大学的硕士学位。
Yi Kuei Chen has served as Apollomics Inc.'s Chief Operating Officer and Director since September 2025. With backgrounds in biotechnology and venture capital, he is a co founder of Maxpro Ventures, where he successfully executed more than 60 private equity investment transactions. Mr. Chen also serves as a member of the Board of Directors of Maxpro Investment Co., Ltd., which is a major shareholder of the Company (see Item 7.A. "Major Shareholders and Related Party Transactions—Major Shareholders."). Before co founding Maxpro, Mr. Chen was the Senior Director of Integral Group, managed its Shanghai branch, and served as a board member of multiple portfolio companies such as Generon Corporation, FusionVax, Inc., BioLite, Inc., and Flora International Group Co., Ltd. From 1999 to 2012, Mr. Chen held various senior management positions in the investment division at Central Investment Holdings. He also served on several corporate boards, such as Concord Fund Company, Singfor Life Insurance Company, and CTCI Corporation.
Ya Chi Huang

Ya Chi Huang,为董事会带来了在台湾生物制药行业的生物技术投资、公司治理和研发方面的丰富经验。Dr. Huang目前在Maxpro Ventures担任助理副总裁,领导国内和国际投资活动。自2024年加入以来,她已成功完成对多家公司的投资,并管理其投资后运营。她还担任ANGENMED Therapeutics的董事。此前,Dr. Huang在Diamond Biofund(6901.TW)担任投资经理,在那里她独立完成了多项投资,并监督了Diamond所有投资组合公司的投后管理。她于2023年参与了Diamond Biofund在台湾证券交易所的IPO。在她职业生涯的早期,她曾在富邦证券投资服务公司担任研究部副经理,在那里她评估了台湾、中国大陆和香港超过150家未上市的生物科技公司,为富邦证券投行业务利润的大幅增长做出了贡献。Dr. Huang的科研背景包括在National Health研究所、生物技术发展中心和中央研究院担任研究职务。她关于EB病毒的博士研究发表在《血液》上,获得第12届TienTe Lee生物医学奖杰出论文奖。Dr. Huang拥有国立台湾大学医学院微生物学博士学位和国立中山大学生物科学硕士学位。


Ya Chi Huang has served as an Independent Director since November 2025. Previously, Dr. Huang served as Investment Manager at Diamond Biofund (6901.TW), where she oversaw post investment management for portfolio companies and participated in Diamond Biofund's IPO on the Taiwan Stock Exchange in 2023. Earlier in her career, she was Deputy Manager in the Research Department at Fubon Securities Investment Services. She holds a Ph.D. in Microbiology from National Taiwan University College of Medicine.
Ya Chi Huang,为董事会带来了在台湾生物制药行业的生物技术投资、公司治理和研发方面的丰富经验。Dr. Huang目前在Maxpro Ventures担任助理副总裁,领导国内和国际投资活动。自2024年加入以来,她已成功完成对多家公司的投资,并管理其投资后运营。她还担任ANGENMED Therapeutics的董事。此前,Dr. Huang在Diamond Biofund(6901.TW)担任投资经理,在那里她独立完成了多项投资,并监督了Diamond所有投资组合公司的投后管理。她于2023年参与了Diamond Biofund在台湾证券交易所的IPO。在她职业生涯的早期,她曾在富邦证券投资服务公司担任研究部副经理,在那里她评估了台湾、中国大陆和香港超过150家未上市的生物科技公司,为富邦证券投行业务利润的大幅增长做出了贡献。Dr. Huang的科研背景包括在National Health研究所、生物技术发展中心和中央研究院担任研究职务。她关于EB病毒的博士研究发表在《血液》上,获得第12届TienTe Lee生物医学奖杰出论文奖。Dr. Huang拥有国立台湾大学医学院微生物学博士学位和国立中山大学生物科学硕士学位。
Ya Chi Huang has served as an Independent Director since November 2025. Previously, Dr. Huang served as Investment Manager at Diamond Biofund (6901.TW), where she oversaw post investment management for portfolio companies and participated in Diamond Biofund's IPO on the Taiwan Stock Exchange in 2023. Earlier in her career, she was Deputy Manager in the Research Department at Fubon Securities Investment Services. She holds a Ph.D. in Microbiology from National Taiwan University College of Medicine.
Hsien Shu Tsai

显树仔自2025年9月起担任独立董事。蔡先生积累了20多年的跨行业专长,横跨投资、业务重组、财务管理等领域。他曾在主要企业集团和创新机构担任领导职务,包括鸿海集团、顶新国际集团和信息产业研究院(III)。他的职业生涯反映了他在资本市场运营、行业分析和财务战略执行方面的良好业绩记录。


Hsien Shu Tsai has served as an Independent Director since September 2025. Mr. Tsai has accumulated more than 20 years of cross industry expertise spanning investment, business restructuring, and financial management. He has held leadership roles across major conglomerates and innovation institutions, including Hon Hai Group, Ting Hsin International Group, and the Institute for Information Industry (III). His career reflects a strong track record in capital market operations, industry analysis, and financial strategy execution.
显树仔自2025年9月起担任独立董事。蔡先生积累了20多年的跨行业专长,横跨投资、业务重组、财务管理等领域。他曾在主要企业集团和创新机构担任领导职务,包括鸿海集团、顶新国际集团和信息产业研究院(III)。他的职业生涯反映了他在资本市场运营、行业分析和财务战略执行方面的良好业绩记录。
Hsien Shu Tsai has served as an Independent Director since September 2025. Mr. Tsai has accumulated more than 20 years of cross industry expertise spanning investment, business restructuring, and financial management. He has held leadership roles across major conglomerates and innovation institutions, including Hon Hai Group, Ting Hsin International Group, and the Institute for Information Industry (III). His career reflects a strong track record in capital market operations, industry analysis, and financial strategy execution.
Hung Hsien Yen

洪显仁,现任新野资本投资有限公司董事长。此外,他还担任STL科技股份有限公司、光洁国际股份有限公司的独立董事。Yen先生拥有国立政治大学会计学学士学位和雪城大学金融学硕士学位。


Hung Hsien Yen,currently serves as the Chairman of SINO SUN CAPITAL INVESTMENT CO., LTD. In addition, he serves as an Independent Director of STL Technology Co., Ltd. and KOJEM INTERNATIONAL CO., LTD. Mr. Yen holds a Bachelor's degree in Accounting from National Chengchi University and a Master's degree in Finance from Syracuse University.
洪显仁,现任新野资本投资有限公司董事长。此外,他还担任STL科技股份有限公司、光洁国际股份有限公司的独立董事。Yen先生拥有国立政治大学会计学学士学位和雪城大学金融学硕士学位。
Hung Hsien Yen,currently serves as the Chairman of SINO SUN CAPITAL INVESTMENT CO., LTD. In addition, he serves as an Independent Director of STL Technology Co., Ltd. and KOJEM INTERNATIONAL CO., LTD. Mr. Yen holds a Bachelor's degree in Accounting from National Chengchi University and a Master's degree in Finance from Syracuse University.

高管简历

中英对照 |  中文 |  英文
Hung Wen Chen

Hung Wen Chen是中国公民台湾居民。


Hung Wen Chen has served as Chairman and Chief Executive Officer since September 2025. Mr. Chen is the Founder and Chairman of Gemtek Technology Co., Ltd. and the former Chairman and CEO of Polaris Pharmaceuticals, Inc., currently serving as an Executive Director of Polaris. In 2019, under his leadership, Polaris underwent a comprehensive strategic reorganization, achieving a remarkable turnaround that culminated in a successful IPO in Taiwan in June 2022. He began his career at Taiwan Semiconductor Manufacturing Company (TSMC), where he was engaged in research and development of semiconductor processes and integrated circuits. Mr. Chen holds a Bachelor of Physics and a Master of Electronics Engineering from National Tsing Hua University, Taiwan.
Hung Wen Chen是中国公民台湾居民。
Hung Wen Chen has served as Chairman and Chief Executive Officer since September 2025. Mr. Chen is the Founder and Chairman of Gemtek Technology Co., Ltd. and the former Chairman and CEO of Polaris Pharmaceuticals, Inc., currently serving as an Executive Director of Polaris. In 2019, under his leadership, Polaris underwent a comprehensive strategic reorganization, achieving a remarkable turnaround that culminated in a successful IPO in Taiwan in June 2022. He began his career at Taiwan Semiconductor Manufacturing Company (TSMC), where he was engaged in research and development of semiconductor processes and integrated circuits. Mr. Chen holds a Bachelor of Physics and a Master of Electronics Engineering from National Tsing Hua University, Taiwan.
Peter Lin

Peter Lin,是一位经验丰富的企业高管和投资者,拥有跨越生物技术、金融和私募股权的杰出职业生涯。他曾在Tanvex Biopharma、Tanvex CDMO、Tanvex Biopharma USA和台湾Tanvex Biologic Corporation担任重要领导职务,负责监督全球实体的财务战略、资本运营和公司治理。在加入Tanvex之前,Peter曾担任Theragent的首席财务官,Theragent是一家专注于基因和细胞治疗的开创性CDMO,在那里他帮助塑造了一家先进治疗领域高增长初创公司的财务基础。Peter的职业生涯也深深扎根于金融行业。作为精品私募股权公司Solarium Capital的负责人和投资经理,他领导了包括科技、食品和饮料以及房地产在内的多个领域的收购和股权投资。在他职业生涯的早期,在获得MBA学位后,Peter加入了WesCorp,担任投资研究经理,在那里他领导了一个信用研究团队,管理着320亿美元的固定收益投资组合——全球最大的结构性信贷投资组合之一。他的团队对美国和国际结构性金融工具进行了深入分析,包括MBS、ABS、CDO和公司债务证券。除了担任执行职务外,Peter还在多家公司的董事会任职,这些公司涵盖生物技术、医疗设备、媒体、出版和房地产私募股权投资企业。他拥有加州大学伯克利分校工商管理学士学位、克莱蒙特研究生大学信息系统硕士学位、南加州大学MBA学位。他还是特许另类投资分析师(CAIA)特许持有人,强调了他在另类投资和全球资本市场方面的专业知识。


Peter Lin has served as Apollomics Inc.'s Chief Financial Officer since September 2025. Mr. Lin (CAIA, MBA, MIS) is a seasoned corporate executive and investor with a distinguished career spanning biotechnology, finance, and private equity. He has held key leadership roles as Chief Financial Officer at Tanvex Biopharma, Tanvex CDMO, Tanvex Biopharma USA, and Tanvex Biologic Corporation in Taiwan, where he oversaw financial strategy, capital operations, and corporate governance across global entities. Prior to Tanvex, Mr. Lin served as CFO of Theragent, a pioneering CDMO specializing in gene and cell therapy, where he helped shape the financial foundation of a high growth startup in the advanced therapeutics space. His career is also deeply rooted in the financial industry. As a principal and investment manager at Solarium Capital, a boutique private equity firm, he led acquisitions and equity investments across diverse sectors including technology, food and beverage, and real estate. Earlier in his career, after earning his MBA, Mr. Lin joined WesCorp as an investment research manager, where he directed a credit research team managing a $32 billion fixed income portfolio—one of the largest structured credit portfolios globally. His team conducted in depth analysis of U.S. and international structured finance instruments, including MBS, ABS, CDOs, and corporate debt securities.
Peter Lin,是一位经验丰富的企业高管和投资者,拥有跨越生物技术、金融和私募股权的杰出职业生涯。他曾在Tanvex Biopharma、Tanvex CDMO、Tanvex Biopharma USA和台湾Tanvex Biologic Corporation担任重要领导职务,负责监督全球实体的财务战略、资本运营和公司治理。在加入Tanvex之前,Peter曾担任Theragent的首席财务官,Theragent是一家专注于基因和细胞治疗的开创性CDMO,在那里他帮助塑造了一家先进治疗领域高增长初创公司的财务基础。Peter的职业生涯也深深扎根于金融行业。作为精品私募股权公司Solarium Capital的负责人和投资经理,他领导了包括科技、食品和饮料以及房地产在内的多个领域的收购和股权投资。在他职业生涯的早期,在获得MBA学位后,Peter加入了WesCorp,担任投资研究经理,在那里他领导了一个信用研究团队,管理着320亿美元的固定收益投资组合——全球最大的结构性信贷投资组合之一。他的团队对美国和国际结构性金融工具进行了深入分析,包括MBS、ABS、CDO和公司债务证券。除了担任执行职务外,Peter还在多家公司的董事会任职,这些公司涵盖生物技术、医疗设备、媒体、出版和房地产私募股权投资企业。他拥有加州大学伯克利分校工商管理学士学位、克莱蒙特研究生大学信息系统硕士学位、南加州大学MBA学位。他还是特许另类投资分析师(CAIA)特许持有人,强调了他在另类投资和全球资本市场方面的专业知识。
Peter Lin has served as Apollomics Inc.'s Chief Financial Officer since September 2025. Mr. Lin (CAIA, MBA, MIS) is a seasoned corporate executive and investor with a distinguished career spanning biotechnology, finance, and private equity. He has held key leadership roles as Chief Financial Officer at Tanvex Biopharma, Tanvex CDMO, Tanvex Biopharma USA, and Tanvex Biologic Corporation in Taiwan, where he oversaw financial strategy, capital operations, and corporate governance across global entities. Prior to Tanvex, Mr. Lin served as CFO of Theragent, a pioneering CDMO specializing in gene and cell therapy, where he helped shape the financial foundation of a high growth startup in the advanced therapeutics space. His career is also deeply rooted in the financial industry. As a principal and investment manager at Solarium Capital, a boutique private equity firm, he led acquisitions and equity investments across diverse sectors including technology, food and beverage, and real estate. Earlier in his career, after earning his MBA, Mr. Lin joined WesCorp as an investment research manager, where he directed a credit research team managing a $32 billion fixed income portfolio—one of the largest structured credit portfolios globally. His team conducted in depth analysis of U.S. and international structured finance instruments, including MBS, ABS, CDOs, and corporate debt securities.
Yi Kuei Chen

Yi Kuei,独立董事,具有生物技术和风险投资背景,自2013年以来是Maxpro Ventures Ltd.的联合创始人兼董事总经理。陈先生在资产管理方面的专业知识使他成功地在美国和亚太地区执行了60多个私募股权投资交易。在联合创立Maxpro Ventures Ltd.之前,他从2012年7月到2013年9月担任Integral Group的高级董事,在那里他共同负责Integral’;的亚洲交易流程,管理其上海品牌,并担任多个投资组合公司的董事会成员,如Generon Corporation,FusionVax,Inc.和BioLite Inc.。从1999年4月到2012年6月,Chen先生在Central Investment Holdings的投资部门担任多个高级管理职位。在此期间,他的成功投资包括Tanox和Biopure等。此外,陈先生自2015年5月起担任风险投资基金Maxpro Investment Co.,Ltd.的董事,Maxpro Capital Management Ltd.自2015年5月起担任管理公司Vertex Ventures Ltd.的董事,Vertex Ventures Ltd.是一家管理公司,自2017年10月起担任Crystal Capital Management Ltd.的董事,自2018年10月以来。陈先生获得了锡拉丘兹大学的工商管理硕士学位和明尼苏达大学的硕士学位。


Yi Kuei Chen has served as Apollomics Inc.'s Chief Operating Officer and Director since September 2025. With backgrounds in biotechnology and venture capital, he is a co founder of Maxpro Ventures, where he successfully executed more than 60 private equity investment transactions. Mr. Chen also serves as a member of the Board of Directors of Maxpro Investment Co., Ltd., which is a major shareholder of the Company (see Item 7.A. "Major Shareholders and Related Party Transactions—Major Shareholders."). Before co founding Maxpro, Mr. Chen was the Senior Director of Integral Group, managed its Shanghai branch, and served as a board member of multiple portfolio companies such as Generon Corporation, FusionVax, Inc., BioLite, Inc., and Flora International Group Co., Ltd. From 1999 to 2012, Mr. Chen held various senior management positions in the investment division at Central Investment Holdings. He also served on several corporate boards, such as Concord Fund Company, Singfor Life Insurance Company, and CTCI Corporation.
Yi Kuei,独立董事,具有生物技术和风险投资背景,自2013年以来是Maxpro Ventures Ltd.的联合创始人兼董事总经理。陈先生在资产管理方面的专业知识使他成功地在美国和亚太地区执行了60多个私募股权投资交易。在联合创立Maxpro Ventures Ltd.之前,他从2012年7月到2013年9月担任Integral Group的高级董事,在那里他共同负责Integral’;的亚洲交易流程,管理其上海品牌,并担任多个投资组合公司的董事会成员,如Generon Corporation,FusionVax,Inc.和BioLite Inc.。从1999年4月到2012年6月,Chen先生在Central Investment Holdings的投资部门担任多个高级管理职位。在此期间,他的成功投资包括Tanox和Biopure等。此外,陈先生自2015年5月起担任风险投资基金Maxpro Investment Co.,Ltd.的董事,Maxpro Capital Management Ltd.自2015年5月起担任管理公司Vertex Ventures Ltd.的董事,Vertex Ventures Ltd.是一家管理公司,自2017年10月起担任Crystal Capital Management Ltd.的董事,自2018年10月以来。陈先生获得了锡拉丘兹大学的工商管理硕士学位和明尼苏达大学的硕士学位。
Yi Kuei Chen has served as Apollomics Inc.'s Chief Operating Officer and Director since September 2025. With backgrounds in biotechnology and venture capital, he is a co founder of Maxpro Ventures, where he successfully executed more than 60 private equity investment transactions. Mr. Chen also serves as a member of the Board of Directors of Maxpro Investment Co., Ltd., which is a major shareholder of the Company (see Item 7.A. "Major Shareholders and Related Party Transactions—Major Shareholders."). Before co founding Maxpro, Mr. Chen was the Senior Director of Integral Group, managed its Shanghai branch, and served as a board member of multiple portfolio companies such as Generon Corporation, FusionVax, Inc., BioLite, Inc., and Flora International Group Co., Ltd. From 1999 to 2012, Mr. Chen held various senior management positions in the investment division at Central Investment Holdings. He also served on several corporate boards, such as Concord Fund Company, Singfor Life Insurance Company, and CTCI Corporation.